HIGH-DOSE CYCLOSPORINE AND CORTICOSTEROIDS FOR PROPHYLAXIS OF ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE

被引:0
作者
SCHWINGHAMMER, TL
BLOOM, EJ
ROSENFELD, CS
WILSON, JW
PRZEPIORKA, D
SHADDUCK, RK
机构
[1] UNIV PITTSBURGH,MONTEFIORE UNIV HOSP,MED CTR,PITTSBURGH CANC INST,ADULT BONE MARROW TRANSPLANT,PITTSBURGH,PA
[2] UNIV PITTSBURGH,SCH MED,DEPT BIOSTAT,PITTSBURGH,PA
关键词
CYCLOSPORINE; METHYL PREDNISOLONE; GRAFT-VERSUS-HOST DISEASE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; PREDNISONE;
D O I
暂无
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Twenty-eight consecutive recipients of HLA-identical sibling marrow grafts received prophylaxis for GVHD with high-dose cyclosporine (CsA) and corticosteroids. CsA 5 mg/kg/day (2.5 mg/kg infused over 4 h twice daily) was started on day -1 and continued until patients could take oral CsA (15 mg/kg/day). CsA doses were adjusted to maintain concentrations between 200-800 ng/ml (whole-blood HPLC) until the tapering period (days 268-361). Methylprednisolone 0.5 mg/kg/day was started on day 7, increased to 1 mg/kg/day during days 15-28, and tapered thereafter until discontinuance on day 194. Low CsA trough levels occurred in 15 patients (54%) during the i.v. administration period. Ten patients (36%) developed grade I and 3 patients (11%) developed grade II acute GVHD; there were no cases of grade III or IV disease. The actuarial incidence of chronic GVHD was 29% at 1 year but 57% at 2 years due to development of chronic GVHD after discontinuation of immunosuppressive agents. High blood CsA concentrations in stable outpatients led to dose-limiting nephrotoxicity. Infections occurred throughout the period of extended immunosuppression (from 6 to 12 months) but were not life-threatening. The actuarial incidence of leukemic relapse was 18% at 1 year and 25% at 2 years. Actuarial survival at 1 and 2 years was 68 and 51%, respectively. Despite the frequent occurrence of low CsA trough levels, this regimen appeared to be effective in preventing acute GVHD. Immunosuppressive prophylaxis beyond 1 year may be required to reduce late-onset chronic GVHD.
引用
收藏
页码:147 / 154
页数:8
相关论文
共 31 条
[1]  
ABESADATERK G, 1990, BONE MARROW TRANSPL, V6, P151
[2]   PHARMACODYNAMIC MONITORING OF CYCLOSPORINE [J].
AWNI, WM .
CLINICAL PHARMACOKINETICS, 1992, 23 (06) :428-448
[3]  
BACIGALUPO A, 1991, BLOOD, V77, P1423
[4]  
BLOOM EJ, 1991, P ASCO, V10, P229
[5]   CYCLOSPORINE ABSORPTION FOLLOWING ORTHOTOPIC LIVER-TRANSPLANTATION [J].
BURCKART, GJ ;
VENKATARAMANAN, R ;
PTACHCINSKI, RJ ;
STARZL, TE ;
GARTNER, JC ;
ZITELLI, BJ ;
MALATACK, JJ ;
SHAW, BW ;
IWATSUKI, S ;
VANTHIEL, DH .
JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (08) :647-651
[6]  
BYERS VS, 1990, BLOOD, V75, P1426
[7]   CYCLOSPORINE, METHOTREXATE, AND PREDNISONE COMPARED WITH CYCLOSPORINE AND PREDNISONE FOR PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE [J].
CHAO, NJ ;
SCHMIDT, GM ;
NILAND, JC ;
AMYLON, MD ;
DAGIS, AC ;
LONG, GD ;
NADEMANEE, AP ;
NEGRIN, RS ;
ODONNELL, MR ;
PARKER, PM ;
SMITH, EP ;
SNYDER, DS ;
STEIN, AS ;
WONG, RM ;
BLUME, KG ;
FORMAN, SJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (17) :1225-1230
[8]  
CRILLEY P, 1990, BONE MARROW TRANSPL, V5, P187
[9]   CYCLOSPORINE AS PROPHYLAXIS FOR GRAFT-VERSUS-HOST DISEASE - A RANDOMIZED STUDY IN PATIENTS UNDERGOING MARROW TRANSPLANTATION FOR ACUTE NONLYMPHOBLASTIC LEUKEMIA [J].
DEEG, HJ ;
STORB, R ;
THOMAS, ED ;
FLOURNOY, N ;
KENNEDY, MS ;
BANAJI, M ;
APPELBAUM, FR ;
BENSINGER, WI ;
BUCKNER, CD ;
CLIFT, RA ;
DONEY, K ;
FEFER, A ;
MCGUFFIN, R ;
SANDERS, JE ;
SINGER, J ;
STEWART, P ;
SULLIVAN, KM ;
WITHERSPOON, RP .
BLOOD, 1985, 65 (06) :1325-1334
[10]  
FORMAN SJ, 1987, TRANSPLANT P, V19, P2605